GRIPHON Open-Label Extension

UPTRAVI—The Only Oral Prostacyclin Pathway Therapy With 7-year Survival Estimates1


The information below is from the open-label extension of the GRIPHON trial.
View the GRIPHON pivotal data for context of the overall population.


Patients enrolled into the pivotal trial (GRIPHON) were eligible to enter the corresponding long-term open-label extension study. In long-term follow-up of patients who were treated with UPTRAVI in the placebo-controlled study (N=574) and the open-label extension study (N=330, of 574), Kaplan-Meier estimates of survival at 1, 2, 5, and 7 years were 92%, 85%, 71%, and 63%, respectively. The median follow-up duration was 4.5 years, and the median exposure of UPTRAVI was 3.0 years.


Overall survival Kaplan-Meier curve for patients randomized to UPTRAVI in GRIPHON and entered into the open-label extension study


Data presented are Kaplan-Meier survival rate estimates (95% CI).